Evidence map›Paper›PMID 41328355›Full record

ArticleTheranostics2026

Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment.

Kang Yi Lee, Heng Sun, Yu Mei, Emily Nickles, Clemence Wei Xia Lai, Sashigala Ponnalagu, Mukul Prasad, Haiyan Liu, Herbert Schwarz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kang Yi LeeNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.
Heng SunDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, 119074 Singapore.
Yu MeiNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.
Emily NicklesNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.
Clemence Wei Xia LaiDepartment of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Hospital, Singapore, Singapore.
Sashigala PonnalaguNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.
Mukul PrasadNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.
Haiyan LiuNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.
Herbert SchwarzNUS Immunology Programme, Life Sciences Institute, Department of Microbiology and Immunology, National University of Singapore, 117545 Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD137 is a powerful T cell costimulatory molecule, and CD137 agonists are being evaluated for human cancer immunotherapy. Urelumab and utomilumab, are two agonistic anti-CD137 antibodies that are most advanced in clinical trials but suffer from liver toxicity and low potency, respectively. Here we describe the development of a new type and formulation of a CD137 agonist that combines high potency and a strong safety profile.

Indexed as

4-1BB LigandImmunotherapyNanoparticlesNasopharyngeal CarcinomaNasopharyngeal NeoplasmsTumor Necrosis Factor Receptor Superfamily, Member 9AnimalsCell Line, TumorFemaleHumansMiceSilicon DioxideT-LymphocytesXenograft Model Antitumor Assays4-1BB LigandSilicon DioxideTNFSF9 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 9cancer immunotherapyCD137mesoporous silica nanoparticlesNPCT cell-based immunotherapy

Identifiers

PMID41328355
PMCPMC12665109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.